Cowen analyst Dan Brennan raised the firm’s price target on Exact Sciences to $76 from $56 and keeps an Outperform rating on the shares. The analyst said the key takeaway from the quarter is the story into 2023 is stronger Cologuard momentum given the pace of margin expansion FCF in 2024 and pipeline opportunity.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS:
